Walker & Dunlop (NYSE:WD) 2026 Investor Day March 10, 2026 09:00 AM ET Company ParticipantsAlison Williams - EVP and Group Head of Multifamily Small Balance GroupChristopher Mahler - President and CEODonald King - EVPGreg Florkowski - EVP and CFOIvy Zelman - EVP of Research and SecuritiesJim Schroeder - EVP of Debt OperationsKelsey Duffey - SVP of Investor RelationsKris Mikkelsen - EVP of Investment SalesMegan Strachan - EVP and CIOSheri Thompson - EVP and Head of Affordable HousingSteve Theobald - EVP and ...

Marqeta Conference Call Summary - March 10, 2026 Company Overview - **Company**: Marqeta (NasdaqGS: MQ) - **Industry**: Payment Processing and Card Issuing Key Points and Arguments Leadership Background - **Mike Milotich**: CEO with 20 years in payments, previously at Visa, PayPal, and Amex. Joined Marqeta 4 years ago, serving as CFO for 3 years before becoming CEO [4][19] - **Patty**: Newly appointed CFO with a decade of experience in payments, previously at JPMorgan and Stripe. Attracted to Marqeta due to its unique customer base and growth potential [7][9][11] Financial Performance - **Gross Profit Growth**: 24% year-over-year, with EBITDA reaching $110 million, a 3.5x increase from 2024 [19] - **Total Payment Volume (TPV)**: Grew 31% for the year, accelerating to 36% in Q4 [19] - **Key Growth Areas**: - Lending and Buy Now, Pay Later (BNPL): Grew approximately 60% in the second half of the year [20] - Expense Management: Over 40% growth in Q4, the highest in three years [20] - Financial Services: Grew over 30% in Q4, marking a significant recovery [20] Guidance and Challenges - **2026 Guidance**: Anticipates about 10 points of headwinds in gross profit growth due to unique items affecting 2026, including renewals and pricing tier adjustments with major clients like Cash App [22][23] - **Cash App Dynamics**: Represents over 40% of Marqeta's business, with pricing adjustments impacting profitability. The company is monitoring customer diversification trends [29][38] Market Position and Competitive Landscape - **Unique Value Proposition**: Marqeta's platform supports various use cases, allowing for customization and scalability, which differentiates it from competitors [62][71] - **Customer Relationships**: Maintains primary partnerships with large clients, ensuring a significant share of their volume remains on Marqeta's platform [39][44] Growth Drivers - **Geographic Expansion**: Notable growth in Europe, with TPV in 2025 being eight times larger than in 2022. The acquisition of TransactPay enhances service offerings in Europe [100][102] - **AI Integration**: Utilizing AI for risk management and customer service to drive efficiency and enhance product offerings [107][131] Profitability and Operating Leverage - **Operating Expenses**: Grew only 1.5% in 2025, with expectations for mid- to high-single-digit growth in 2026. The company is leveraging AI to maintain low expense growth while scaling operations [75][76] - **Path to Profitability**: Expected to break even in the first half of 2026, with a projected net income of $10 million in the second half [78] Macro Environment and Risks - **Market Volatility**: While macroeconomic factors pose risks, current spending trends remain stable. The company is closely monitoring discretionary spending and consumer health [81][85] - **Customer Diversification**: Engaging with clients to understand their plans for the year, which may mitigate risks associated with customer movement [83] Additional Important Insights - **Value-Added Services**: Marqeta is focusing on enhancing its value-added services, which contributed 7% to gross profit in 2025, double that of 2024 [140] - **Personalization in Rewards**: Plans to implement AI-driven personalized rewards, a significant shift in the card business [108] This summary encapsulates the key insights from Marqeta's conference call, highlighting the company's performance, strategic direction, and market dynamics.

Summary of Applied Materials Conference Call Company Overview - **Company**: Applied Materials (NasdaqGS: AMAT) - **Date**: March 10, 2026 - **Event**: Canaccord Genuity Tech and Industrial Conference Key Industry Insights - **Silicon Revenue Growth**: Expected to exceed 20% in 2026, constrained by clean room space availability, with potential for double-digit growth in 2027 [3][4] - **AI Demand**: Strong demand from cloud service providers, with projected capital expenditures for data center AI reaching $600 billion in 2026 and $700 billion in 2027 [4] - **Leading-Edge Semiconductor Components**: Market constrained, particularly in advanced logic, DRAM, and advanced packaging solutions [4][10] Customer Engagement and Supply Chain - **Two-Year Visibility**: Applied Materials is working with customers to gain two years of visibility into equipment needs, which is crucial for managing supply chain capacity [6][7] - **Supplier Relationships**: Over 2,000 suppliers are engaged to ensure capacity meets demand, with a focus on regional self-sufficiency and reduced reliance on single sources [11] Market Dynamics - **Data Center Demand**: Data centers now account for 30% of wafer demand on leading-edge technology, surpassing PC components and expected to overtake smartphone components by 2029 [13] - **DRAM and High-Bandwidth Memory (HBM)**: 15% of DRAM wafer starts are allocated to HBM, which requires more intensive equipment and processes, presenting a growth opportunity for Applied Materials [17][18] - **NAND Market**: Bit demand remains strong, but wafer starts have been flat due to technological advancements that increase bit density without needing more wafers [24][25] Financial Performance and Projections - **Advanced Packaging Growth**: Expected to grow faster than the overall semiconductor equipment market, which is projected to grow over 20% in 2026 [20][21] - **Service Business Growth**: Projected low double-digit growth, supported by an increasing installed base of equipment and new service products [30][31] - **Gross Margins**: Recent guidance indicates a record gross margin of 49.3%, with expectations for continued improvement driven by a more valuable portfolio and disciplined pricing strategies [36][39] Strategic Initiatives - **EPIC Lab**: A new facility aimed at fostering long-term partnerships with customers, enhancing R&D capabilities, and accelerating innovation [40][41] - **Capital Allocation**: Aiming to return 80%-100% of free cash flow to investors, with recent buybacks totaling $4 billion [49][50] Risks and Considerations - **China Market Exposure**: Applied Materials has a significant presence in China, primarily in mature node technologies, with expectations for stable demand despite geopolitical concerns [26][27] - **Trade Restrictions**: Current trade rules are constraining growth opportunities in the Chinese market, particularly for memory products [28] Conclusion - Applied Materials is positioned for strong growth driven by demand in AI, advanced packaging, and DRAM markets, while maintaining a focus on supply chain management and customer engagement. The company is also investing in strategic initiatives like the EPIC Lab to enhance innovation and long-term partnerships.

Summary of Abeona Therapeutics Conference Call Company Overview - **Company**: Abeona Therapeutics (NasdaqCM:ABEO) - **Product**: ZEVASKYN, a gene therapy for recessive dystrophic epidermolysis bullosa (RDEB) Key Points Launch Progress - The launch of ZEVASKYN is progressing well, with the first patient treated in December 2025, following FDA approval in April 2025 [3][4] - Initial delays were due to assay optimization related to sterility testing, which has since been resolved [4][6][9] Assay Optimization - A false positive issue was identified with a rapid sterility assay, which has been addressed through optimization to reduce the likelihood of false positives [4][7][10] - The company is confident that the risk of false positives has been significantly minimized, although empirical evidence will be gathered from ongoing runs [10][12] Market Opportunity - The target patient population for ZEVASKYN is approximately 750 patients in the U.S. with moderate to severe RDEB, leading to an estimated total addressable market of about 1,500 treatment opportunities [16][17] - The urgency for treatment is heightened due to the risk of complications such as squamous cell carcinomas in these patients [17] Patient Journey - The patient journey from identification to treatment currently takes about 4-5 months, with expectations to reduce this timeframe as processes are streamlined [21][31] - The manufacturing time for the product is approximately 25 days once a biopsy is collected [22][31] Treatment Center Expansion - Abeona aims to activate 5-7 qualified treatment centers (QTCs) in 2026, with ongoing engagement from additional centers expressing interest [52][53] - Currently, two centers are actively treating patients, with plans to onboard more centers to increase patient throughput [27][47] Demand and Patient Identification - As of the call, 50 patients have been identified, with a high conversion rate expected due to the severity of their conditions [41][43] - The company is actively working to increase the number of patients treated as more centers come online and administrative processes improve [37][51] Capacity and Manufacturing - Current manufacturing capacity is 6 slots per month, with plans to ramp up to 10 slots in the second half of the year [57][59] - Long-term plans include the potential to double capacity to 20 slots, contingent on facility upgrades [61] Future Strategy - The company is focused on the successful launch of ZEVASKYN before discussing pipeline assets, with profitability expected in 2026 if treatment rates exceed three patients per month [67][69] - There is interest in expanding the use of ZEVASKYN for less severe patients and other applications, such as post-surgical treatment for pseudosyndactyly [62] Conclusion - Abeona Therapeutics is on track with the launch of ZEVASKYN, addressing initial challenges and focusing on expanding treatment capacity and patient access. The company is optimistic about achieving profitability in the near future as demand grows and operational efficiencies improve.

Genmab Conference Call Summary Company Overview - **Company**: Genmab (NasdaqGS: GMAB) - **Year**: 2025 was highlighted as a strong year for Genmab, with significant financial growth and advancements in their late-stage pipeline, including three key programs: EPKINLY, Rina-S, and pivekimab [3][4] Financial Performance - **Revenue Growth**: Strong revenue growth was reported, alongside disciplined operational expenditure management, leading to profit flowing to the bottom line [3] - **Pipeline Progress**: The company has three late-stage programs with meaningful clinical data expected to support potential launches in 2027 [4] Key Programs and Commercial Opportunities EPKINLY - **Market Potential**: EPKINLY is viewed as a blockbuster medicine with a potential market opportunity exceeding $3 billion [6] - **Therapeutic Indications**: The program is expanding into earlier lines of therapy, particularly in second-line follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) [6][8] - **Clinical Data**: Positive performance in initial phases and robust uptake in community settings were noted [8][27] - **Regulatory Timeline**: Expected readouts for frontline DLBCL and second-line DLBCL trials in 2026, with potential regulatory submissions leading to a launch in 2027 [15][16] Rina-S - **Market Potential**: Rina-S has a peak opportunity estimated at over $2 billion, targeting multiple subsegments in gynecologic oncology [9][10] - **Clinical Trials**: Three ongoing phase 3 trials are in progress, with the first registrational readout expected in 2026 [9][10] - **Differentiation**: The program is positioned as potentially best-in-class with differentiated efficacy and safety profiles, allowing for longer durations of therapy [34][35] Pivekimab - **Market Potential**: Pivekimab is also projected to be a multi-billion dollar opportunity, with two ongoing phase 3 trials in head and neck cancer [11][12] - **Regulatory Timeline**: Expected readouts for these trials in 2026, with a potential launch in 2027 [11][12] Commercialization Strategy - **Market Readiness**: Genmab has been building its commercial infrastructure in the U.S., Japan, and Europe, preparing for the launches of Rina-S and pivekimab [18][22] - **Track Record**: The company has successfully launched TIVDAK and EPKINLY, which provides confidence for future launches [24][22] Competitive Landscape - **EPKINLY vs. Competitors**: EPKINLY is positioned to penetrate earlier lines of treatment and gain market share against other CD20 bispecific therapies [25][26] - **Rina-S Differentiation**: Rina-S is expected to outperform existing ADCs in ovarian cancer due to its efficacy across various folate receptor alpha expression levels [34][35] Milestones and Catalysts for 2026 - **Key Readouts**: Two phase 3 readouts for EPKINLY in DLBCL, and the first registrational data for Rina-S and pivekimab are anticipated in 2026, leading to potential launches in 2027 [52][54] - **Focus on Deleveraging**: The company aims to reduce its debt from the acquisition of Merus, targeting a gross leverage ratio of three times or below by the end of 2027 [50][51] Conclusion - Genmab is positioned for significant growth with multiple late-stage programs expected to yield positive clinical data and commercial opportunities in the coming years. The company’s strategic focus on commercialization and market readiness, alongside a strong pipeline, sets a promising outlook for future performance [4][12][54]

Bio-Techne 2026 Conference Summary Company Overview - **Company**: Bio-Techne (NasdaqGS: TECH) - **Industry**: Life Science Tools and Diagnostics Key Market Insights Pharma Market - Pharma represents approximately **30%** of Bio-Techne's revenue - Exited December quarter with **low double-digit growth**, marking the fifth consecutive quarter of double-digit growth [6][7] - Concerns regarding MFN pricing and tariffs were alleviated, leading to continued strong performance in large pharma [7][8] Biotech Market - Biotech accounts for about **20%** of revenue - Exited Q2 with **mid-single-digit declines** in biotech, which is seen as a positive outcome given a **40%** decline in biotech funding in the first half of 2025 [9][12] - Recent funding trends show signs of recovery, with funding increasing by **over 90%** exiting December [14][15] - M&A activity among large pharma acquiring biotechs is increasing, indicating a positive outlook for new investors [16] Academic Market - Academic market contributes a little over **20%** of global revenues, split evenly between Europe and the U.S. - European academic market shows **low- to mid-single-digit growth**, while U.S. academic market has stabilized with **low single-digit declines** [24][28] - Recent approval of a **1% increase** in NIH funding is a positive development, although the impact on spending is still uncertain [32][36] Asia Market - Asia accounts for **16%-17%** of revenue, with half from China - China has seen three consecutive quarters of growth, with double-digit growth in the rest of Asia [41][45] - Optimism is returning in China regarding government funding for biotechs, with increased licensing activity from pharma [62] Financial Guidance - For fiscal year 2026, Bio-Techne expects to exit Q4 with **mid-single-digit growth** [66] - Concerns about timing of recovery in funding translating into spending, with historical lag of **2-3 quarters** noted [79][81] - Anticipated headwinds from two large GMP customers, which have been significant contributors to revenue, are expected to lessen in Q4 [88][91] Growth Drivers - The cell therapy franchise has shown resilience, with **30% growth** among remaining customers excluding two large GMP customers [102] - Over **80 customers** are in clinical trials, indicating a robust pipeline [104] - The company expects a **floor of 20% growth** in a normal market for the remaining customer base [121] M&A Strategy - Bio-Techne remains committed to M&A as a priority for capital deployment, focusing on quality over quantity in potential acquisitions [141][156] - Areas of interest include cell therapy and organoids, with a belief that these sectors will continue to grow significantly [157] AI and Future Outlook - AI is viewed as a significant enhancement for the industry, with expectations that it will drive growth in life science tools over the next several years [175][180] - The company is actively using AI to develop next-generation proteins, which are expected to be a key growth area [175][189] Margin Expansion - Bio-Techne anticipates **100 basis points margin expansion** in 2026, driven by growth in differentiated products [196][199] - Historical growth rates suggest that mid-single-digit to high single-digit growth should yield at least **50 basis points** in margin expansion [199][203] Conclusion - Bio-Techne is positioned for growth across various markets, with positive trends in pharma, biotech, and academic sectors. The company is focused on strategic M&A, leveraging AI for innovation, and maintaining margin expansion through differentiated product offerings.

Summary of Relmada Therapeutics Conference Call Company Overview - **Company Name**: Relmada Therapeutics (NasdaqGS: RLMD) - **Founded**: 2012 as a spinoff from Cornell University, went public in 2014, and listed on Nasdaq in 2019 - **Focus**: Initially focused on Central Nervous System (CNS) but shifted strategy to include oncology, specifically bladder cancer with NDV-01 [5][6] Core Product: NDV-01 - **Indication**: Bladder cancer, which accounts for 4% of all cancers in the U.S. and is typically non-lethal but can last for many years [8] - **Mechanism**: NDV-01 is a gel formulation that allows for sustained-release delivery of chemotherapy (Gemcitabine and Docetaxel) directly into the bladder, simplifying administration [11][12] - **Administration**: Takes less than five minutes, allowing for more patients to be treated in outpatient settings [11][12] Clinical Data - **12-Month Complete Response (CR) Rates**: - 76% in high-risk non-muscle invasive bladder cancer (NMIBC) [17] - 80% in BCG-unresponsive patients, which is noted as the highest in this patient group [17] - **Comparison with Other Treatments**: - GemDoce (Gemcitabine and Docetaxel) has a 60% CR rate in similar patient populations, indicating NDV-01's potential for superior efficacy [24][27] Market Opportunity - **Current Treatments**: Existing FDA-approved drugs for BCG-unresponsive NMIBC show CR rates between 19% and 45%, indicating a significant unmet need [47][100] - **Target Population**: Intermediate-risk bladder cancer has a larger patient population (75,000-80,000) compared to high-risk (5,000), presenting a substantial market opportunity [52] Development Strategy - **Upcoming Studies**: Plans to initiate an 87-patient study for BCG-unresponsive high-risk NMIBC in mid-2026, with endpoints focused on CR and duration of response [50][65] - **Regulatory Path**: Aiming to be the first to have a label for second-line therapy in bladder cancer, which is currently lacking [48] Financial Update - **Recent Financing**: Raised $160 million at $4.75 per share, oversubscribed with $540 million in demand [83] Competitive Landscape - **Current Competitors**: Other companies are developing treatments for intermediate-risk bladder cancer, but face challenges such as the need for FGFR testing, which is not widely adopted [77][79] - **Unique Selling Proposition**: NDV-01's ease of use and established delivery method may provide a competitive edge over more complex therapies [109] Additional Insights - **Urologist Preferences**: Urologists prefer to avoid radical cystectomy due to low reimbursement rates and high complication rates associated with the procedure [95][97] - **Patient Management**: The goal is to improve recurrence-free survival and reduce the burden of care for patients with bladder cancer [61][62] This summary encapsulates the key points discussed during the conference call, highlighting Relmada Therapeutics' strategic focus, product development, market potential, and competitive positioning in the bladder cancer treatment landscape.

Citigroup Conference Call Summary Company Overview - **Company**: Citigroup (NYSE:C) - **Market Capitalization**: Approximately $187 billion - **CEO**: Jane Fraser, in her fifth year as CEO - **Stock Performance**: Citigroup's stock is up 53% under her tenure, outperforming the bank index which is up 31% [1][5] Economic and Market Dynamics - **Global Economy**: The underlying economy is performing well, with good business momentum and consumer spending up about 5% in February in the U.S. [6][7] - **Corporate Health**: Corporate balance sheets are strong, with significant investments in AI and technology. The M&A market is vibrant, with companies looking for consolidation opportunities [6][7] - **Deregulation Impact**: Deregulation is positively affecting market confidence and speed of transactions [7] - **Middle East Situation**: The ongoing crisis in the Middle East is a significant concern, particularly regarding oil prices. If oil prices remain above $100 for an extended period, it could negatively impact global GDP growth by approximately 15 basis points [8][9] Investment Banking and Market Outlook - **Investment Banking Fees**: Expecting mid-teens growth in investment banking fees year-over-year, driven by M&A and equity capital markets [23] - **Market Business Growth**: Anticipating mid-teens growth in the markets business as well, with strength in both equities and fixed income [23] - **Operating Efficiency**: Targeting around 60% operating efficiency for the full year, with some severance expenses front-loaded in Q1 [24] Capital and Regulatory Environment - **Regulatory Changes**: Awaiting proposals from regulators regarding Basel III and stress capital buffers, with optimism about potential outcomes [19][20] - **Capital Discipline**: Emphasis on maintaining capital discipline and returning capital to shareholders when high-return opportunities are not available [39][78] Retail Banking and Wealth Management - **Integration of Retail and Wealth**: The integration of retail banking and wealth management is expected to drive revenue growth, with retail banking showing revenue growth in the low to mid-20s% [49] - **Client Experience**: Focus on enhancing client experience and leveraging partnerships to improve offerings [48][52] Credit Card Business - **Franchise Growth**: Citigroup is the number 3 credit card franchise in the U.S., with strong growth in loyalty and engagement programs [65] - **Co-brand Relationships**: Emphasis on expanding co-brand relationships and converting existing portfolios to co-brands for growth [65] Future Outlook - **Return on Tangible Common Equity (ROTCE)**: Confident in achieving a ROTCE of 10%-11% for the year, supported by revenue growth and operational efficiencies [29][32] - **Investment in AI**: Significant investments in AI are expected to drive productivity and revenue opportunities [75] - **Long-term Strategy**: The focus remains on client acquisition, deepening relationships, and maintaining a disciplined approach to capital allocation [76][78] Key Messages for Investors - **Foundational Progress**: Citigroup has laid a strong foundation for future growth, with clarity in strategy and interconnected business units [82] - **Divestitures and Simplification**: Progress on divestitures and organizational simplification has improved decision-making and accountability [83] - **Positive Momentum**: Anticipation of continued revenue growth and improved returns, with a competitive edge in the market [84]

AnaptysBio FY Conference Summary Company Overview - AnaptysBio is a biotechnology company with over 20 years of experience in developing antibodies, currently preparing to spin off its biopharma operations into a new entity called First Tracks Biotherapeutics [6][4] - The company has two successful programs: - Jemperli (dostarlimab), an oncology drug sold by GSK, which generated approximately $1.4 billion in revenue last year, translating to about $100 million in royalties for AnaptysBio [19][111] - Imsidolimab, which is expected to have a Phase 2 readout by the end of the year and is anticipated to be sold by Vanda [6][6] Financial Structure Post-Separation - AnaptysBio will retain a royalty-based financial structure with high EBIT margins in the mid-high 90% range, minimal operational expenses (less than $10 million annually), and fewer than 10 full-time employees [17][25] - The company expects to be cash flow positive by mid-2027, with a projected need for $100 million to fund the biopharma business into Q3 of 2027 and $200 million to fully fund it into the latter half of 2028 [32][34] Pipeline and Product Development ANB033 (CD122 Antagonist) - ANB033 is being developed for Celiac Disease and Eosinophilic Esophagitis (EoE), with a Phase 1b trial design that includes two cohorts: one undergoing a gluten challenge and another with patients showing signs of mucosal injury [38][50] - The trial aims to measure histological outcomes and symptom severity, with results expected in Q4 of this year [68][66] - The company believes it has a competitive edge due to its dual-targeting mechanism, which blocks both IL-2 and IL-15 pathways [70][78] EoE Program - The EoE trial is set to initiate with a 50-patient cohort, focusing on histological outcomes and patient-reported outcomes (PRO) [84][85] - The approach targets TH2 CD4 cells and ILC2s, differentiating it from Dupixent, the only approved therapeutic for EoE, which targets eosinophils directly [90][91] Competitive Landscape - AnaptysBio faces competition from other companies targeting the IL-15/CD122 pathway, including Teva and Novartis, but believes its dual-targeting approach provides a distinct advantage [71][75] - The company is optimistic about its potential to address a broader patient population, including those who are Dupixent-experienced and Dupixent-naive [95][96] Royalty Business and Future Outlook - The royalty business is anchored by Jemperli, which is projected to grow significantly, with GSK aiming for peak sales of $2.7 billion by 2029, resulting in close to $400 million in royalties for AnaptysBio [111][113] - The company is focused on protecting and maximizing the value from existing royalties rather than expanding into new drugs [111][112] - AnaptysBio anticipates exiting the year with two commercial-stage royalties, including imsidolimab, which is awaiting approval for generalized pustular psoriasis [122][122] Conclusion - AnaptysBio is strategically positioning itself for growth through the separation of its biopharma operations, a strong pipeline of innovative therapies, and a robust royalty business model that leverages existing successful products [6][4][111]

Centene (NYSE:CNC) FY Conference Summary Company Overview - **Company**: Centene Corporation - **Event**: Barclays Global Healthcare Conference - **Date**: March 10, 2026 Key Points Current Business Performance - Centene reaffirms adjusted EPS guidance of greater than $3 for 2026, with all three core business lines (Medicaid, Medicare, and Marketplace) on track so far [4][8] - Medicaid membership is expected to be approximately 3.5 million by the end of Q1 2026, down from 5.5 million in December 2025 [5][10] - The company is optimistic about the execution of ongoing trend initiatives impacting Medicaid and Medicare [4][8] Marketplace Dynamics - Membership in the Marketplace has decreased from 5.5 million in December to 3.6 million in February 2026, with expectations of reaching around 3.5 million by the end of the quarter [5][10] - The distribution of metal tiers shows a shift, with mid-30s% in Bronze, high teens% in Gold, and just under 50% in Silver [6][11] - Higher utilization patterns in specialty pharmacy are noted, particularly in the Silver tier, which may impact risk adjustment calculations [6][17] Risk Adjustment and Data Insights - Centene is tracking a Wakely report due at the end of March, which will provide insights into market contraction and membership distribution across metal tiers [7][13] - The company anticipates being in a net payable position for risk adjustment in 2026, but will remain conservative until full data is available [13][16] - The focus is on understanding therapeutic classes and disease states to inform risk adjustment strategies [17][18] Medicaid Trends and Initiatives - Medicaid cost trend for 2026 is expected to be around 4.5%, down from mid-6% in 2025 [19][20] - Centene is actively working on initiatives to combat fraud, waste, and abuse, which is estimated to account for 10% of all healthcare spending [22][23] - The company has developed 75 algorithms to identify suspect claims and is enhancing data sharing with state partners to improve program integrity [22][25] Medicare and Part D Insights - The individual PDP industry growth is expected to accelerate from 1% in 2025 to close to 3% in 2026, with Centene taking market share [31] - The company aims for a Part D margin of around 2% for 2026, with a focus on maintaining a favorable cost structure [32][33] - Medicare Advantage margins are projected to be slightly below break-even in 2026, with a goal of achieving break-even by 2027 [35][36] Capital Deployment Strategy - Centene plans no share repurchase in 2026, focusing instead on a partial redemption of $1 billion of 2027 notes to recalibrate debt levels [39][40] - The company is exploring ways to generate cash and monetize assets as part of its capital deployment strategy [40] Future Outlook on Medicaid Policy - Membership levels in Medicaid are expected to decline slightly due to tighter eligibility verification processes [41][42] - The impact of OB3 and work requirements will be assessed on a state-by-state basis, with guidance from CMS expected to influence future membership and margins [44][46] Additional Insights - The dialogue with CMS regarding Medicare rates has focused on ensuring that trend assumptions are reflective of current realities, particularly in light of COVID-19 data [36][37] - Centene is preparing for potential shifts in risk pools due to changes in Medicaid rates and eligibility requirements [46] This summary encapsulates the key insights and strategic directions discussed during the conference, highlighting Centene's performance, market dynamics, and future outlook in the healthcare sector.